Expand all sections

Eptacog alfa (activated)

NovoSeven

Extended indication Extension of indication to include treatment of severe postpartum haemorrhage
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Eptacog alfa (activated)
Domain Cardiovascular diseases
Reason of inclusion Indication extension
Main indication Other non-oncological hematological medications
Extended indication Extension of indication to include treatment of severe postpartum haemorrhage
Proprietary name NovoSeven
Manufacturer Novo Nordisk
Route of administration Intravenous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Submission date October 2021
Expected Registration August 2022
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.